Clinical trials: B-cell Malignancy, Low-grade
CLL
Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL
A Phase 2 study of Zandelisib with Venetoclax (VEN) and Rituximab (R) in subjects with Relapsed/Refractory CLL.
- Trial name
- CORAL (NCT05209308)
- Testing
- Zandelisib, Rituximab, Venetoclax
- Where
- 4 sites in United States
- Sponsor
- MEI Pharma, Inc.
Chronic Lymphocytic Leukemia With 17p Deletion, Small Lymphocytic Lymphoma With 17p Deletion
A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion
An Open-label, Single arm, Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma with 17p Deletion
- Trial name
- NCT01744691
- Testing
- Ibrutinib
- Where
- 55 sites in United States, Australia and 7 more
- Volunteers
- 145 people
- Sponsor
- Pharmacyclics LLC.
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
The purpose of this study is to evaluate the multi-lineage hematopoietic chimerism for unrelated umbilical cord blood (UCB) grafts pooled from two to three cord blood units.
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT01500161
- Testing
- Busulfan, Clofarabine, Fludarabine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Texas Oncology Cancer Center
CD20-Positive Lymphoid Malignancies, Chronic Lymphoid Leukemia
Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers
This is a Phase 1 study evaluating the safety of ABT-263 administered in combination with rituximab in participants with CD20-positive lymphoproliferative disorders.
- Conditions
- CD20-Positive Lymphoid Malignancies, Chronic Lymphoid Leukemia, Hematological Malignancies, Non-Hodgkin's Lymphoma
- Trial name
- NCT00788684
- Testing
- rituximab, ABT-263
- Where
- 6 sites in United States, Australia
- Volunteers
- 29 people
- Sponsor
- AbbVie
Mature B-cell Malignancies
Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies
This is a Phase 1/2 study of zanubrutinib in Japanese participants with mature B-cell malignancies. This study intends to assess the use of zanubrutinib as an investigational agent to develop new treatment options for Japanese…
- Trial name
- NCT04172246
- Testing
- Zanubrutinib
- Where
- 15 sites in Japan
- Volunteers
- 55 people
- Sponsor
- BeiGene
B Cell Lymphoma, B Cell Leukemia
Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors
This study is a single-arm, single-center, investigator-initiated clinical trial. The primary objective is to evaluate the safety and preliminary efficacy of administering universal CD19 CAR-T cells to subjects with refractory…
- Conditions
- B Cell Lymphoma, B Cell Leukemia, B Cell Malignancy
- Trial name
- NCT06662227
- Testing
- Single dose injection of certain dose of UWD-19, MMF Immunosuppression
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Wondercel Biotech (ShenZhen)
CLL / SLL, CLL (Chronic Lymphocytic Leukemia)
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
This is a Phase 3, randomized, open-label, multicenter study comparing rocbrutinib (LP-168) versus pirtobrutinib in adult participants with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma…
- Conditions
- CLL / SLL, CLL (Chronic Lymphocytic Leukemia), CLL, Refractory, CLL, Relapsed
- Trial name
- NCT07342478
- Testing
- Rocbrutinib, Pirtobrutinib
- Where
- 6 sites in United States
- Volunteers
- 306 people
- Sponsor
- Newave Pharmaceutical Inc
Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
Unity NHL - A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + Umbralisib with or without Bendamustine and Umbralisib alone in Patients with Previously Treated Non-Hodgkin's Lymphoma
- Conditions
- Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma
- Trial name
- UNITY-NHL (NCT02793583)
- Testing
- Ublituximab, Umbralisib, Bendamustine
- Where
- 168 sites in United States, Australia and 7 more
- Volunteers
- 710 people
- Sponsor
- TG Therapeutics, Inc.
Non-Hodgkin Lymphoma
A Rollover Study of CC-122
The purpose of the study is to provide CC-122 treatment to participants who have been receiving treatment in other CC-122 clinical trials investigating CC-122 for more than 5 years (CC-122-ST-001 [NCT01421524], CC-122-ST-002…
- Trial name
- NCT05688475
- Testing
- CC-122, Dexamethasone
- Where
- 7 sites in United States, France and 2 more
- Volunteers
- 12 people
- Sponsor
- Bristol-Myers Squibb
Hematologic Cancer
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, pharmacokinetics, and preliminary efficacy of…
- Trial name
- NCT05753501
- Testing
- ABBV-101
- Where
- 51 sites in United States, Canada and 7 more
- Volunteers
- 135 people
- Sponsor
- AbbVie
Lymphoma
Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma
RATIONALE: Diagnostic imaging procedures using radiolabeled monoclonal antibodies may improve the ability to detect and stage non-Hodgkin's lymphoma.
- Trial name
- NCT00003337
- Testing
- immunoscintigraphy, technetium Tc 99m epratuzumab
- Where
- 8 sites in United States, Austria and 3 more
- Volunteers
- 100 people
- Sponsor
- Gilead Sciences
Leukemia, Lymphoma
VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders
RATIONALE: Drugs used in chemotherapy, such as VNP40101M, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00304005
- Testing
- laromustine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Vion Pharmaceuticals
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell
A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas
AEG35156 has shown early evidence of activity in patients with advanced indolent B-cell lymphomas in Phase 1 trials and merits further evaluation in this disease.
- Trial name
- NCT00768339
- Testing
- AEG35156 antisense IV infusion
- Where
- 7 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- Aegera Therapeutics
Chronic Lymphocytic Leukemia
Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)
This is a randomized (1:1), open-label, multicenter, active-controlled study in patients with previously treated CD23+ and CD20+ relapsed CLL.
- Trial name
- LUCID (NCT00391066)
- Testing
- FCR + Lumiliximab, FCR
- Where
- 194 sites in United States, Argentina and 21 more
- Volunteers
- 627 people
- Sponsor
- Biogen
Chronic Lymphocytic Leukemia (CLL)
A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).
The purpose of this open-label, single-arm study was to evaluate the impact of venetoclax on the quality of life of participants including those with with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL; a type of…
- Trial name
- VENICE II (NCT02980731)
- Testing
- Venetoclax
- Where
- 33 sites in Argentina, Australia and 8 more
- Volunteers
- 210 people
- Sponsor
- AbbVie
Chronic Lymphocytic Leukemia (CLL)
Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia
This study is to provide idelalisib (IDELA) to individuals with relapsed, previously treated chronic lymphocytic leukemia (CLL) who have limited treatment options and are not eligible for other Gilead-sponsored studies.
- Trial name
- NCT02136511
- Testing
- Idelalisib, Rituximab
- Where
- 8 sites in United States, Ireland and 2 more
- Sponsor
- Gilead Sciences
Chronic Lymphocytic Leukemia, B-cell Malignancies
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
The primary objective of the study for Cohort 1 and Cohort 2 is to assess the anticancer activity of emavusertib in combination with zanubrutinib in participants with CLL.
- Trial name
- NCT07271667
- Testing
- Emavusertib, Zanubrutinib
- Where
- 11 sites in United States, Italy and 1 more
- Volunteers
- 108 people
- Sponsor
- Curis, Inc.
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin
A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to determine the recommended Phase 2 dose regimen or the maximum tolerated dose of JNJ-67856633 in participants with relapsed/ refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
- Trial name
- NCT03900598
- Testing
- JNJ-67856633
- Where
- 47 sites in United States, Australia and 10 more
- Volunteers
- 226 people
- Sponsor
- Janssen Research & Development, LLC
Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL)
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
This study is a Phase 1 dose-escalation and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV111. The study will enroll patients with relapsed/refractory large B-cell lymphoma (LBCL) and chronic…
- Conditions
- Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL), Lymphoma, Large B-Cell, Diffuse (DLBCL), Chronic Lymphocytic Leukemia (CLL)
- Trial name
- NCT06528301
- Testing
- UB-VV111, rapamycin
- Where
- 9 sites in United States, Australia
- Volunteers
- 106 people
- Sponsor
- Umoja Biopharma
Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma
Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
Primary Objective: To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) for SAR245409 when administered in combination with rituximab or bendamustine plus rituximab Secondary Objectives: To determine…
- Conditions
- Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT01410513
- Testing
- SAR245409
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- Sanofi